|
Early Stage:
Stage 0, I, or II:
T1-3, Node Negative:
-
CTSU 40101: Randomized Study, Cyclosphosphamide and Doxorubicin (4 vs. 6 Cycles) vs.
Paclitaxel (12 Weeks vs. 18 Weeks) as Adjuvant Therapy for
Women with Node-Negative Breast Cancer: A 2x2 Factorial,
Phase III
-
CTSU PACCT-1: Program for the Assessment of Clinical
Trial Tests (PACCT-1):
Trial Assigning Individualized Options for Treatment: The
TAYLORx Trial
Stage I, II, III:
-
SWOG 0221: Phase III Trial of Continuous
Schedule AC + G vs Q 2 Week Schedule AC, Followed by
Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks
as Post-Operative Adjuvant Therapy in Node-Positive or
High-Risk Node Negative Breast Cancer.
-
SWOG 0230: Phase III Trial of LHRH Analog
Administration During Chemotherapy to Reduce Ovarian Failure
Following Standard Adjuvant Chemotherapy in Early Stage,
Hormone-Receptor Negative Breast Cancer.
-
SWOG 0307: Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast
Cancer.
-
CTSU 24-02: Phase III Trial Evaluating the
Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women
with Endocrine Responsive Breast Cancer. (SOFT Trial)
-
NSABP B-42: A Clinical Trial to Determine the Efficacy
of Five Years of Letrozole Compared to Placebo in Patients
Completing Five Years of Hormonal Therapy Consisting of an
Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in
Prolonging Disease-Free Survival in Postmenopausal Women
with Hormone Receptor Positive Breast Cancer
-
NASBP B-40: A Randomized Phase III Trial of Neoadjuvant
Therapy in Patients with Palpable and Operable Breast Cancer
Evaluating the Effect on Pathologic Complete Response (pCR)
of Adding Capecitabine or Gemcitabine to Docetaxel when
Administered Before AC with or without Bevacizumab and
Correlative Science Studies Attempting to Identify
Predictors of High Likelihood for pCR with Each of the
Regimens
-
JMA17R: A Double Blind Randomization to Letrozole or
Placebo for Women Previously Diagnosed With Primary Breast
Cancer Completing Five Years of Adjuvant Aromatase Inhibitor
Either as Initial therapy or After Tamoxifen (Including
Those in The MA.17 Study)
-
CTSU N063D: Adjuvant Lapatinib and/or Trastuzumab
Treatment Optimisation (ALTTO) study: A Randomised,
Multi-Centre, Open-Label, Phase III Study of Adjuvant
Lapatinib, Trastuzumab, Their Sequence and Their Combination
in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Stage II, III:
Stage IV:
-
SWOG 0226: Phase III Randomized Trail of Anastrozole vs Anastrozole and Fulvestrant as First Line
Therapy for Post Menopausal Women with Metastatic Breast
Cancer.
-
NSABP B-37: A Randomized Clinical Trial of
Adjuvant Chemotherapy for Radically Resected Loco-regional
Relapse of Breast Cancer
-
SWOG 0500: A Randomized Phase III Trial to test the
Strategy of Changing therapy Versus Maintaining Therapy for
Metastatic Breast cancer Patients who have Elevated
Circulating Tumor Cells at First Follow-Up Assessment
-
CTSU E1105: A Randomized Phase III Double-Blind
Placebo-Controlled Trial of First-line Chemotherapy and
Trastuzumab with or without Bevacizumab for Patients with
HER-2/NEU Over-expressing Metastatic Breast Cancer
-
CTSU C40302: Endocrine Therapy with or without
Inhibition of EGF and HER2 Growth Factor Receptors: A
Randomized, Double-Blind, Placebo-Controlled Phase III Trial
of Fulvestrant with or without Lapatinib (GW572016) for
Postmenopausal Women with Estrogen-Receptor Positive
Advanced Breast Cancer
For more information on the above clinical
trials:
Cheryl Patz, RN, OCN, CCRC, 360.715.4133
Return to previous page
|